Your session is about to expire
Remicade vs Cimzia
Introduction
For patients with autoimmune disorders such as rheumatoid arthritis, Crohn's disease, or psoriasis, certain drugs that interfere with the body's immune response can help in managing symptoms and prevent damage to healthy tissues. Remicade and Cimzia are two such biologic agents that are often prescribed for these conditions. They each target a protein called tumor necrosis factor (TNF), which plays a role in driving inflammation in the body, but they do have some differences.
Remicade (infliximab) is a chimeric monoclonal antibody against TNF-alpha. It binds to TNF, reducing inflammation by preventing this cytokine from interacting with its receptors on cells. Remicade is usually administered via an intravenous infusion at a hospital or clinic.
Cimzia (certolizumab pegol), on the other hand, is classified as an anti-TNF drug conjugated to polyethylene glycol (PEG). The PEGylation extends the half-life of certolizumab pegol and allows it to be given less frequently than some other anti-TNF medications. Unlike Remicade, Cimzia can be self-administered through subcutaneous injections.
Remicade vs Cimzia Side By Side
| Attribute | Remicade | Cimzia |
|---|---|---|
| Brand Name | Remicade | Cimzia |
| Contraindications | Worsening of infections, reactivation of Hepatitis B virus in carriers. Cannot be taken with immunosuppressants without consulting a doctor. | Worsening of infections, reactivation of Hepatitis B virus in carriers. Cannot be taken with immunosuppressants without consulting a doctor. |
| Cost | The cost of one single-use vial (100mg) of Remicade averages around $1,300. | The price for two pre-filled syringes of Cimzia (200 mg each) averages about $3,500 and lasts about a month. |
| Generic Name | Infliximab | Certolizumab pegol |
| Most Serious Side Effect | Signs of an allergic reaction, severe stomach pain or diarrhea, vision problems, heart issues, symptoms related to infections, neurological disorders. | Signs of an allergic reaction, serious infections, unusual bleeding, rapid heart rate, pale skin. |
| Severe Drug Interactions | Immunosuppressants | Immunosuppressants |
| Typical Dose | For rheumatoid arthritis, 3 mg/kg given as an intravenous infusion at 0, 2, and 6 weeks, then every eight weeks thereafter. | Initiated with a loading dosage of 400 mg at weeks 0, 2, and 4. Maintenance dosing begins with 200 mg every two weeks or 400 mg every four weeks. |
What is Remicade?
Infliximab, commonly known as Remicade, was one of the first drugs classified as TNF (tumor necrosis factor) inhibitors. This class of medication marked a significant advancement from traditional treatments for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. Infliximab was approved by the FDA in 1998. It works by binding to TNF molecules in your bloodstream and inhibiting their ability to cause inflammation – effectively neutralizing them before they can provoke an immune response.
On the other hand, Certolizumab pegol, or Cimzia, is another biologic drug that blocks the action of TNF but differs slightly in its mechanism and structure than Infliximab - it is PEGylated anti-TNFα medication which extends its duration within the body allowing for less frequent dosing intervals compared to non-PEGylated medications like infliximab.
While both are used broadly in treating various autoimmune diseases like rheumatoid arthritis or Crohn's disease; however, due to these differences alongside individual patient factors may make one more suitable over another on a case-to-case basis.
What conditions is Remicade approved to treat?
Remicade is approved for the treatment of several inflammatory conditions:
- Rheumatoid arthritis, in combination with methotrexate
- Crohn's disease and ulcerative colitis
- Ankylosing spondylitis, a type of spinal arthritis
- Psoriasis and psoriatic arthritis
- Pediatric patients with active forms of certain diseases such as Crohn's disease (in children 6 years or older), juvenile idiopathic arthritis (in children 2 years or older), pediatric plaque psoriasis (in children 4 years or older)
Cimzia has been approved to treat:
- Adult patients with moderately to severely active rheumatoid arthritis
- Adult patients with active psoriatic arthritis.
- Adults with ankylosing spondylitis.
- Adults suffering from moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Moderately to severely active Crohn’s Disease in adult patients who have not responded adequately to conventional therapy.
How does Remicade help with these illnesses?
Remicade aids in managing autoimmune disorders by blocking the activity of tumor necrosis factor-alpha (TNF-alpha), a protein in the body that promotes inflammation. It does this by binding to TNF-alpha, thereby preventing it from interacting with its receptors and triggering an inflammatory response. TNF-alpha is a cytokine, which are small proteins that play crucial roles in cell signalling and can influence the immune system's behavior. It is thought that individuals with certain autoimmune conditions have abnormally high levels of TNF-alpha, leading to excessive inflammation and tissue damage. Therefore, by inhibiting TNF-alpha, Remicade can decrease inflammation, help manage symptoms associated with these conditions - such as pain or swelling - and improve patients' quality of life.
On the other hand, Cimzia also works by neutralizing TNF alpha but has been engineered for better patient convenience as it requires less frequent dosing than Remicade due to its unique PEGylated structure which prolongs its effects on reducing inflammation.
What is Cimzia?
Cimzia is a brand name for certolizumab pegol, which is an anti-TNF (tumor necrosis factor) drug. It works by blocking the action of TNF, a substance in the body that causes inflammation. Cimzia was first approved by the FDA in 2008. As Cimzia differs from other anti-TNF drugs like Remicade (infliximab), it has unique characteristics and side-effects profile. Specifically, due to its PEGylated form, it does not cross over into the placenta and hence can be safely used during pregnancy unlike infliximab or other similar medications. Furthermore, common adverse events associated with Cimzia are usually minor and include symptoms like upper respiratory infection or urinary tract infection but serious infections such as tuberculosis have also been reported less frequently just like with any other anti-TNF drugs including Remicade.
What conditions is Cimzia approved to treat?
Cimzia is a TNF blocker primarily used for the treatment of autoimmune diseases. The U.S. Food and Drug Administration (FDA) has approved Cimzia for the management of:
- Moderate to severe rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Adult Crohn's disease that did not respond well to other treatments
How does Cimzia help with these illnesses?
Tumor Necrosis Factor (TNF) is a cell signaling protein involved in systemic inflammation and one of the cytokines that make up the acute phase reaction. It's heavily implicated in autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Cimzia works by neutralizing TNF in the body, thereby relieving some of the symptoms of these disorders. Its action on other inflammatory cytokines may also be part of its mechanism as an anti-inflammatory drug. Since it does not significantly affect Interleukin-6 levels, another important pro-inflammatory cytokine, it is sometimes prescribed when a patient does not respond well to other “typical” TNF inhibitors (such as Remicade), or may be combined with these drugs.
How effective are both Remicade and Cimzia?
Both infliximab (Remicade) and certolizumab pegol (Cimzia) are successful options in treating various autoimmune disorders, such as rheumatoid arthritis, Crohn's disease, and psoriasis. They were approved by the FDA a few years apart; Remicade in 1998 and Cimzia in 2008. Both drugs act on the same target: tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine involved in immune responses. Their effectiveness has been evaluated through several clinical trials.
In a double-blind study conducted between 2013-2015 comparing their effectiveness for patients with psoriatic arthritis, both Remicade and Cimzia showed comparable efficacy reducing symptoms of inflammation. The safety profiles were also similar across groups receiving either drug.
A systematic review from 2017 noted that while both medications can effectively manage symptoms of rheumatoid arthritis from the early stages of treatment, there may be slight differences based on patient-specific factors like age or concurrent health conditions. A major distinction is that Remicade must be administered via intravenous infusion at a healthcare facility whereas Cimzia is given through subcutaneous injection which can be self-administered at home.
A meta-analysis published in 2020 indicated that similar to other anti-TNF therapies, both infliximab and certolizumab pegol show better effectiveness than placebo for managing active Crohn's disease flares. However due to individual variation in response to these medications it is still crucial to monitor each patient closely irrespective of medication choice.
Overall while these two TNF blockers have shown very similar efficacy and safety profiles some patients might prefer one over another depending on specific needs such as ease of administration or potential side effects including propensity towards infections or allergic reactions.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Remicade typically prescribed?
The dosages for Remicade and Cimzia vary depending on the condition being treated. For adults with rheumatoid arthritis, a typical dose of Remicade is 3 mg/kg given as an intravenous infusion at 0, 2 and 6 weeks, then every eight weeks thereafter. The dosage can be increased to a maximum of 10 mg/kg or the frequency increased to every four weeks if necessary.
For adults with Crohn's disease or ulcerative colitis using Cimzia, the common starting dose is a series of two subcutaneous injections of 400mg initially, followed by another set of doses at week two and week four; afterwards it's typically reduced to one injection (200mg) every two weeks. Depending on patient response and tolerance, your doctor may adjust this regimen as needed.
In all cases remember that these medications should always be administered under medical supervision due to their potent effects and potential side effects.
At what dose is Cimzia typically prescribed?
Cimzia treatment is typically initiated with a loading dosage of 400 mg (given as two subcutaneous injections of 200 mg each) at weeks 0, 2 and 4. After the initial phase, maintenance dosing begins with either 200 mg every two weeks or a dose of 400 mg every four weeks. It's important to note that Cimzia's efficacy can be seen within the first few weeks but could take longer for some patients; therefore, if there isn't an apparent response after several weeks, medication adjustments may need to be discussed with your healthcare provider.
What are the most common side effects for Remicade?
Common side effects of Remicade can include:
- Reactions at the injection site
- Upper respiratory infections (common cold, sinus infections)
- Headache
- Rash
- Coughing
- Stomach pain
On the other hand, common adverse reactions to Cimzia may involve:
- Upper respiratory infections (like those experienced with Remicade)
- Urinary tract infection
- Rash
- Fatigue and fever
Are there any potential serious side effects for Remicade?
While Remicade and Cimzia both are used to treat autoimmune diseases, they can have different side effects. In rare cases, serious side effects of Remicade may include:
- Signs of an allergic reaction: difficulty breathing; swelling of your face, lips, tongue or throat
- Skin reactions: rash, itching hives
- Severe stomach pain or diarrhea
- Vision problems such as blurred vision or double vision
- Heart issues such as chest discomfort and irregular heartbeats
- Symptoms related to infections like fever, chills and sore throat
- Neurological disorders including seizures, tingling in the extremities
On the other hand, severe side effects for Cimzia might include:
- Allergic reactions characterized by symptoms like hives; difficulty breathing; swelling in your face or throat.
- Serious infections leading to symptoms such as fever or persistent coughing.
- Unusual bleeding (nosebleeds), bruising easily.
- Rapid heart rate accompanied with shortness of breath.
- Pale skin indicating signs of anemia.
If you experience any severe adverse effect from either medication consult a healthcare provider immediately.
What are the most common side effects for Cimzia?
Cimzia, like Remicade, is used to treat several chronic inflammatory conditions. However, the side effects can differ slightly. Potential side effects of Cimzia may include:
- Upper respiratory infections such as stuffy or runny nose and sore throat
- Urinary tract infection
- Headache or migraine
- Rash
- Fatigue or lethargy
- Nausea
- Dizziness or vertigo
These are not all possible side effects of Cimzia. If you experience any other symptoms that concern you while taking this medication, consult with your healthcare professional immediately.
Are there any potential serious side effects for Cimzia?
While Cimzia is generally well-tolerated, it can sometimes cause serious side effects. Some of these may include:
- Signs of an allergic reaction such as hives, itching, difficulty breathing or swallowing, swelling in your face or throat
- Skin problems like a rash that's severe and blistering or peeling
- Conditions affecting the nervous system which might show symptoms like numbness or tingling, problems with vision, weakness in your arms or legs
- Heart issues characterized by chest discomfort, shortness of breath, feeling light-headed and fainting
- Liver problems leading to loss of appetite, stomach pain (especially on the upper right side), dark urine coloration and yellowing of skin or eyes (jaundice).
If you experience any such reactions while taking Cimzia therapy for conditions like rheumatoid arthritis or Crohn's disease among others - immediately contact your healthcare provider.
Contraindications for Remicade and Cimzia?
Both Remicade and Cimzia, along with other biologic medications, may worsen symptoms of infections in some people. If you notice your infection symptoms worsening or an increase in fatigue, fever, weight loss, or behavior changes signaling possible neurological events like seizures or vision problems please seek immediate medical attention.
Neither Remicade nor Cimzia can be taken if you are taking immunosuppressants without consulting your doctor; doing so could excessively dampen your immune response leading to serious infections. Always tell your physician which medications you are taking as they will have to carefully manage the dosages to prevent dangerous interactions between these drugs.
Furthermore, both Remicade and Cimzia may cause reactivation of Hepatitis B virus in carriers of this virus; hence a screening for Hepatitis B is necessary before starting therapy with either drug.
How much do Remicade and Cimzia cost?
For the brand name versions of these drugs:
- The cost of one single-use vial (100mg) of Remicade averages around $1,300. Since treatment typically involves infusions every 4 to 8 weeks, daily costs can vary but generally range from $16 to $32.
- The price for two pre-filled syringes of Cimzia (200 mg each) averages about $3,500 and lasts about a month depending on your dosage schedule. This works out to approximately $117/day.
Thus, if you are in the higher dosage frequency for Remicade (i.e., every 4 weeks), then brand-name Cimzia is significantly more expensive on a per-day treatment basis. Please note that cost should not be a primary consideration in determining which of these drugs is right for you.
Currently, there are no generic versions available for either Remicade or Cimzia as they are biologics and biosimilar products have not been approved by FDA yet.
Popularity of Remicade and Cimzia
Infliximab, known by its brand name Remicade, was estimated to have been prescribed to approximately 1.2 million people in the U.S. in 2020. Infliximab accounted for just over 16% of prescriptions among tumor necrosis factor inhibitors (TNF inhibitors), a class of drugs primarily used to manage autoimmune diseases.
Certolizumab pegol, marketed under the brand name Cimzia, was prescribed to around 160 thousand people in the USA during the same year. This constitutes nearly 2% of TNF inhibitor prescriptions countrywide. Although certolizumab holds a smaller market share compared to infliximab, it has seen steady growth since its introduction in 2008 due mainly to its unique formulation that bypasses placental transfer and may be preferred for women considering pregnancy.
Both these medications are biologics targeting TNF-alpha and are commonly used in conditions like rheumatoid arthritis, psoriatic arthritis and Crohn's disease among others.
Conclusion
Both Remicade (infliximab) and Cimzia (certolizumab pegol) are widely used in the treatment of various autoimmune diseases, including Crohn's disease, rheumatoid arthritis, and psoriatic arthritis. Their effectiveness is well-documented by a multitude of clinical studies demonstrating their superiority over placebo treatments. In some cases, these two drugs may be used in conjunction with each other under careful supervision from a healthcare provider.
Their mechanisms of action differ; Remicade binds to both free and bound TNF-alpha while Cimzia only binds to soluble TNF-alpha molecules. This results in different prescribing patterns based on the individual patient’s health status and requirements.
Remicade often serves as a first-line biologic option due to its long-standing history of use whereas Cimzia might be considered as an alternative or adjuvant therapy for patients who do not respond adequately to initial therapies or have specific needs such as self-administration at home since it comes in pre-filled syringes suitable for subcutaneous injection.
Neither drug is available in generic form which can make them costly especially for out-of-pocket payers. Both require therapeutic monitoring particularly during the initiation phase because they may take several weeks before noticeable effects occur due to their slow onset of action.
The side effect profiles are comparable between these two medications: infections being one common concern given that they suppress immune function. It’s vital that patients closely monitor any changes in symptoms when starting therapy and seek immediate medical help if new troubling signs arise such as persistent fever, shortness of breath or unusual fatigue which could indicate serious infections.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Deeks, E. D. (2016, October 4). Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases. BioDrugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40259-016-0197-y
- Maini, S. R. (2004, May). Infliximab treatment of rheumatoid arthritis. Rheumatic Disease Clinics of North America. Elsevier BV.http://doi.org/10.1016/j.rdc.2004.01.009
- Nahra, V., Hasbani, G. E., Chaaya, M., & Uthman, I. (2020). The Use of Infliximab (Remicade®) for the Treatment of Rheumatic Diseases at a Tertiary Center in Lebanon: A 17-Year Retrospective Chart Review. Mediterranean Journal of Rheumatology. Convin SA.http://doi.org/10.31138/mjr.31.4.400
- El-Hag, K., Dercken, H.-G., Prenzel, R., & Hölzle, E. (2008, April). Medikamenten-induzierte Alveolitis unterInfliximab-/Azathioprin-Therapie. Pneumologie. Georg Thieme Verlag KG.http://doi.org/10.1055/s-2007-1016443
- Deeks, E. D. (2013, January). Certolizumab Pegol. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-013-0009-3
- Dhillon, S. (2014, June). Certolizumab Pegol: A Review of Its Use in Patients with Axial Spondyloarthritis or Psoriatic Arthritis. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-014-0239-z
- Voulgari, P. V., Kaltsonoudis, E., Papagoras, C., & Drosos, A. A. (2012, September 6). Adalimumab in the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy. Informa Healthcare.http://doi.org/10.1517/14712598.2012.721771
- Bolge, S. C., Carter, C. T., Mueller, C. S., Bailey, R. A., & Ingham, M. P. (2012, December). Comparative Multidatabase Analysis of Dosing Patterns and Infusion Intervals for the First 12 Infliximab Infusions in Patients With Rheumatoid Arthritis. Clinical Therapeutics. Elsevier BV.http://doi.org/10.1016/j.clinthera.2012.10.010
- Patel, A. M., & Moreland, L. W. (2010, November). Certolizumab pegol: a new biologic targeting rheumatoid arthritis. Expert Review of Clinical Immunology. Informa UK Limited.http://doi.org/10.1586/eci.10.69
- Soriano, E., Rosa J., & Sabelli M. (2010, August). Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis. Medical Devices: Evidence and Research. Informa UK Limited.http://doi.org/10.2147/mder.s7504